News

Walgreens announces pricing of senior notes

BY Michael Johnsen

DEERFIELD, Ill. — Walgreens on Monday announced that it has priced an underwritten public offering of senior notes, the net proceeds from which will be used to repay — in full — money that was borrowed to fund the cash consideration in its acquisition of a 45% stake in Alliance Boots and for general corporate purposes, including its previously announced USA Drug acquisition.

The senior notes consist of:

  • $550 million of floating rate notes due 2014;

  • $750 million of 1% notes due 2015;

  • $1 billion of 1.8% notes due 2017;

  • $1.2 billion of 3.1% notes due 2022; and

  • $500 million of 4.4% notes due 2042.

The sale of the notes is expected to close on Sept. 13.

The joint book-running managers for the offering are Goldman Sachs, Merrill Lynch, Pierce, Fenner & Smith, J.P. Morgan Securities, Morgan Stanley and Wells Fargo Securities.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

News

Upsher-Smith introduces Nexa Plus prenatal vitamins

BY Alaric DeArment

 MAPLE GROVE, Minn. — Drug maker Upsher-Smith Labs has introduced a new product to its prenatal vitamin line, the company said Tuesday.

The drug maker announced the launch of Nexa Plus capsules, a once-daily, prescription vitamin that contains 350 mg of life’s DHA, a plant-based and fish-free omega-3 fatty acid; 1.25 mg of folic acid; and 250 mcg of the B vitamin biotin.

Other nutrients include vitamins C, D3, E, B6, folic acid, calcium, iron and the stool softener decussate calcium. The Nexa product line also includes Nexa Select capsules, PreNexa capsules and B-Nexa tablets.


Interested in this topic? Sign up for our weekly DSN Collaborative Care e-newsletter.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

News

Sagent launches drug to prevent chemotherapy-induced vomiting

BY Alaric DeArment

 SCHAUMBURG, Ill. — Sagent Pharmaceuticals has launched a drug used to treat complications related to chemotherapy, the drug maker said.

The Schaumburg, Ill.-based company announced the launch of ondansetron injection, used to prevent nausea and vomiting associated with emetogenic cancer chemotherapy and also to prevent nausea and vomiting that follows surgery.

Various versions of the drug had sales of $49 million during the 12-month period that ended in June, according to IMS Health.


Interested in this topic? Sign up for our weekly DSN Collaborative Care e-newsletter.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES